Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Scripps Health
same
Age
18–72
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age \> 55 years or
2. Age \< 55 and LVEF \< 45% or creatinine clearance \< 60 ml/min
3. Ability to cover the cost of the transplant, necessary medications, and transportation/housing.
4. Caregiver must be available while outpatient
Guidelines for Cladribine-Melphalan-based conditioning:
Bone Marrow Failure States Severe Aplastic Anemia (relapsed following immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic features or hemosiderosis)
AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second induction attempt)
ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse failing reinduction attempt)
MDS (RAEB, RAEBiT, CMMoL)
CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd chronic or accelerated phase following gleevec therapy
Hodgkin's lymphoma (first or greater relapse)
Non-Hodgkin's Lymphoma
Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR Sensitive or refractory relapse
Indolent Histology Second or greater relapse
Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy)
Multiple Myeloma (10% residual plasmacytosis following anthracycline-based chemotherapy or residual disease following autologous transplant)
Waldenstrom Macroglobulinemia (must have failed either purine analogue-based chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias)
Guidelines for total lymphoid irradiation-based conditioning
MDS (RA, RARS)
CLL (Rai stage III or IV - must have received at least two different treatment regimens in the past)
Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy)
Renal Cell Cancer (metastatic disease at multiple sites)
Malignant Melanoma (metastatic disease at multiple sites)
